The company posted a RON6.3 million net loss, from RON20 million profit in the first nine months of 2024, mainly caused by foreign exchange fluctuations.
Pro-forma EBITDA was 20.4% above the year-earlier level.
The most important advances were recorded on the divisions of hospitals (+39.2%) and clinics (+19.2%), followed by laboratories (+16.1%) and pharmacies (+11.2%).
The company has accelerateed the strategic direction of development in the field of personalized medicine, by launching Longevity100+, the first and largest genetic testing program in the region. The initiative aims to democratize access to genetic testing, shifting the focus from treating advanced diseases to early risk identification and prevention.
At the same time, the Group has accelerated the development and implementation of its own AI-based solutions aimed at supporting the advanced analysis of medical images and data.
„The data we report today reflects the transformation we are building: we are moving from screening and treatment medical services to personalized health plans, based on accurate data provided by genetics, state-of-the-art technology and the expertise of our multidisciplinary medical teams – a model that differentiates us in the long term and strengthens our competitive advantage” said Mihai Marcu, President and CEO of MedLife Group.
At the same time, MedLife Group continued to expand the medical infrastructure nationwide through a series of organic projects that were completed during this period. Thus, in the hospital division, the Group marked the inauguration of the new operating block of MedLife Craiova Hospital, an investment that brings state-of-the-art technology and top surgical standards to patients in Oltenia. In the clinics division, MedLife scored an investment of over 3 million euros in Pitesti by opening a new large medical unit designed to offer integrated services – from consultations and lab tests, to imaging and day hospitalization. Also, in the laboratory division, the company inaugurated the first fully automated laboratory in Brasov, an investment of over 2 million euros, which contributes to increasing processing capacity, reducing tests analysis times and higher accuracy of results.
Looking ahead, the company wants to accelerate projects based on the research component and actively contribute to improving the medical act and the patient experience. A defining project in this regard is the recently launched pilot research initiative in medical imaging, in which MedLife radiologists work side by side with an AI algorithm trained to recognize subtle patterns and contribute to the writing of standardized, complete and accurate imaging reports that will aim to increase the level of accuracy in establishing the diagnosis.
MedLife has a RON4.6 billion capitalization after its shares have added 52% since the start of the year, amid deals worth RON243 million.
(English version by Catalina Apostoiu)